Pharma Technology Focus – Issue 51
In this issue: Efficiency in Australia’s pharma industry, India’s move to biosimilars, painkillers that don’t rely on opioids, NHS England’s funding of HIV drug PrEP, whether stem cell transplants can be used to treat MS, and more.
US Precision Medicine Initiative gears up for a massive e-health drive
Personalised medicine has long been an aim of advanced health systems, and the US is looking to move ever closer to this goal with the Precision Medicine Initiative Cohort Program, a massive e-health database storing detailed health data over many years from at least a million American volunteers. Chris Lo finds out what it takes to set up a public health database of this magnitude.
Going global: India’s big biosimilar move
With biosimilar versions of effective but expensive biologic treatments set to unlock major opportunities around the world, does India’s pharma sector and regulatory system have what it takes to repeat its generics success with much more complex biosimilars?
Is the stage set for global drug price regulation?
French President Francois Hollande is hoping to encourage the adoption of international drug price regulation among the G7 states. The move could bring transparency and affordability of drug pricing so vital medicines can be accessed much more widely, but is the world ready for such a bold step?
Rule-breakers: rehabilitating wayward clinical researchers
The US-based Professionalism and Integrity Program was developed with funding from the National Institutes of Health to help researchers who have made key ethical and professional failures to change their ways and regain their research privileges. Course director Dr James DuBois discusses common causes of compliance slip-ups and how researchers can move forward without repeating them.